Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate cancer~* Measurable disease on computed tomography (CT) or evaluable disease on bone scan with an elevated PSA~* For patients who did not initially present with metastatic disease, definitive treatment with either radical prostatectomy or external beam radiation is permitted~* Documented progression on (a) two prior hormone treatments AND (b) one or two chemotherapy regimens~* Documented progression on two prior hormone therapies is defined as orchiectomy followed by anti-adrenal medication upon progression OR gonadotropin-releasing hormone (GnRH) analog +/- androgen receptor blocker with addition or subtraction upon progression; castrate level of testosterone must be documented at study entry~* Documented progression on taxane-based chemotherapy; in addition, patients may have failed a second prior chemotherapy regimen~* Palliative radiation therapy for metastatic disease is allowed only if less than 25% of total body bone marrow was irradiated; 28 days must have elapsed since completion of radiation therapy (RT) with bone marrow recovery; soft tissue disease irradiated in the prior 2 months may not be designated as measurable disease~* ECOG performance score of 0-2~* Absolute neutrophil count (ANC) \>= 1500/uL~* Platelet count \>= 100,000/uL~* Creatinine clearance \>= 45 mL/min~* Serum total bilirubin =\<1.5 mg/dL~* Alkaline phosphatase =\< 3x the upper limit of normal (ULN) for the reference lab (=\< 5x the ULN for patients with known hepatic metastases) and no upper limit for patients with known bone metastases~* Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) =\< 3x the ULN for the reference lab (=\< 5x the ULN for patients with known hepatic metastases)~* Patients must be recovered from both acute and late effects of any prior surgery, radiotherapy or other antineoplastic therapy~* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial~* Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter~* Patients with pleural or peritoneal effusions are eligible~* Willingness and ability to take vitamin supplementation and steroid premedication as specified in protocol~* Patients with superficial bladder cancer or skin cancer who have second malignancy within 5 years which was removed with curative intent~Exclusion Criteria:~* Active infection or with a fever \>= 38.5 degrees Celsius (C) within 3 days of the first scheduled protocol treatment~* Patients with brain metastases~* Prior malignancy within the past 5 years, except for curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder cancer~* Known hypersensitivity to any of the components of oxaliplatin or pemetrexed~* Received radiotherapy to more than 25% of their bone marrow, or patients who received any radiotherapy within 4 weeks of entry~* Received treatment with strontium~* Receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment~* Life expectancy \< 6 months~* Peripheral neuropathy \>= Grade 2~* Any other medical condition, including mental illness or substance abuse~* History of allogeneic transplant~* Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated, or both)~* Inability to stop nonsteroidal anti-inflammatory drugs (NSAIDS) for a period of 2 days before, the day of, and 2 days following administration of Alimta; 5 days before, the day of, and 2 days following administration of Alimta for long-acting NSAIDS

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy and enzyme inhibitor) (Type: EXPERIMENTAL): Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).